Alpine Im­mune Sci­ences, Janux said to be look­ing at pos­si­ble sales — re­ports

Two clin­i­cal-stage biotechs are po­ten­tial­ly the next ac­qui­si­tion tar­gets in bio­phar­ma, ac­cord­ing to Wednes­day af­ter­noon re­ports from Bloomberg News.

T cell en­gager biotech Janux Ther­a­peu­tics is said to be weigh­ing a pos­si­ble sale, ac­cord­ing to one re­port from the news ser­vice. Mean­while, im­mune drug de­vel­op­er Alpine Im­mune Sci­ences is al­so ex­plor­ing a sale as it re­ceives takeover in­ter­est, per an­oth­er Bloomberg re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER